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Background: Among women worldwide, breast cancer is the most commonly diagnosed cancer, and the second
leading cause of cancer-related deaths. Improved understanding of breast tumourigenesis may facilitate the
development of more effective therapies. Peroxisome proliferator-activated receptor (PPAR)γ is a transcription factor
that regulates genes involved in insulin sensitivity and adipogenesis. Previously, we showed, using 7,12-dimethylbenz
[a] anthracene (DMBA)-treated haploinsufficient PPARγ mice, that PPARγ suppresses breast tumour progression;
however, the PPARγ expressing cell types and mechanisms involved remain to be clarified. Here, the role of PPARγ
expression and activation in mammary epithelial cells (MG) with respect to DMBA-mediated breast tumourigenesis was
investigated.
Methods: PPARγ MG knockout (PPARγ-MG KO) mice and their congenic, wild-type controls (PPARγ-WT) were treated
once a week for six weeks by oral gavage with 1 mg DMBA dissolved in corn oil and maintained on a normal chow
diet. At week 7, mice were randomly divided into those maintained on a normal chow diet (DMBA Only; PPARγ-WT:
n = 25 and PPARγ-MG KO: n = 39) or those receiving a diet supplemented with the PPARγ ligand, rosiglitazone (ROSI,
4 mg/kg/day) (DMBA + ROSI; PPARγ-WT: n = 34 and PPARγ-MG KO: n = 17) for the duration of the 25-week study.
Results: Compared to DMBA Only-treated PPARγ-WTs, both breast tumour susceptibility and serum levels of
proinflammatory and chemotactic cytokines, namely IL-4, eotaxin, GM-CSF, IFN-γ, and MIP-1α, were decreased among
PPARγ-MG KOs. Cotreatment with ROSI significantly reduced breast tumour progression among PPARγ-WTs, correlating
with increased BRCA1 and decreased VEGF and COX-2 protein expression levels in breast tumours; whereas, surprisingly
DMBA + ROSI-treated PPARγ-MG KOs showed increased breast tumourigenesis, correlating with activation of COX-2.
Conclusion: These novel data suggest MG-specific PPARγ expression and signaling is critical during breast
tumourigenesis, and may serve as a strong candidate predictive biomarker for response of breast cancer patients to the
use of therapeutic strategies that include PPARγ ligands.
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Breast cancer is the most commonly diagnosed form of
cancer among women worldwide with 1.7 million new
cases identified and over 500,000 breast cancer-related
deaths in 2012 [1]. Despite advances in early detection
and treatment for many types of breast tumours, it re-
mains difficult to predict which patients will suffer from
aggressive forms of disease or respond poorly to current
therapies. More work is needed to identify biomarkers
that may reduce the number of deaths and improve
quality of life for patients diagnosed with breast cancer.
Peroxisome proliferator-activated receptor (PPAR)γ is
a transcription factor that is primarily expressed in adi-
pocytes [2], as well as mammary epithelial (MG) cells
[3], and a majority of human breast tumour cell lines
[4,5]. It regulates the expression of genes involved in
glucose and lipid metabolism, with an emerging role in
breast tumourigenesis [6]. The mechanisms by which
PPARγ regulates gene expression are best reviewed else-
where [7]. Ligands for PPARγ include synthetic drugs
from the thiazolidinedione (TZD) class [8]. Rosiglitazone
(ROSI), a TZD family member, is a potent activator of
PPARγ and prescribed to successfully treat some
patients with Type II diabetes [9].
A breast tumour suppressor role for PPARγ was first
demonstrated in vitro when treatment of human MCF-7
and MDA-MB-231 breast cancer cells with PPARγ ligands
resulted in decreased cell proliferation, promotion of
differentiation, and induction of apoptosis [4,5,10,11]. We
provided the first direct in vivo evidence that PPARγ
normally stops the growth and spread of breast and other
tumour progression in a 7,12-dimethylbenz[a] anthracene
(DMBA)-treated haploinsufficient PPARγ(+/-) mouse
model [12]. To better define the mammary cell-specific
importance of PPARγ during breast tumourigenesis, we
more recently showed that in vivo expression and activa-
tion of PPARγ in both virgin mammary stromal adipocytes
and post-lactational secretory epithelial cells protects
against DMBA-induced breast tumourigenesis [13,14].
Here we sought to explore the role of virgin mammary
epithelial cell (MG)-specific PPARγ signaling and acti-
vation during DMBA-mediated breast tumourigenesis
using conditional PPARγ-MG KO mice. It was hypoth-
esized that MG-specific PPARγ expression is protective
during breast tumourigenesis, and that this effect could
be amplified via ROSI activation of PPARγ in MG cells.
Here we unveil evidence that MG-specific PPARγ ex-
pression enhances early breast tumour events; whereas,
more importantly activation of MG-specific PPARγ-
dependent signaling reduces breast tumour progression.
Results
Based on observations in our lab and previous reports
[15], PPARγ-WT and PPARγ-MG KO mice are notprone to spontaneous tumour formation, suggesting
any tumours that arose were a result of DMBA initi-
ation. In regards to tumourigenic response, overall sur-
vival (OS) for PPARγ-WT and PPARγ-MG KO mice are
shown in Figure 1A and B respectively, and for DMBA
Only-treated and DMBA+ ROSI-treated mice are shown
in Figure 1C and D respectively. Within genotypes,
DMBA + ROSI-treated PPARγ-WTs had a significantly
improved OS compared to their respective DMBA Only-
treated controls (respective median OS: 21.5 vs. 17 weeks,
p < 0.05). Interestingly, among PPARγ-MG KO mice,
cotreatment significantly worsened OS outcomes com-
pared to DMBA Only-treated controls (respective me-
dian OS: 21 weeks vs. undefined, p < 0.05). Among
DMBA Only-treated groups, PPARγ-MG KO mice
showed a strong statistically significant advantage in OS
compared to PPARγ-WTs (p < 0.0001); however, this
difference was not retained between DMBA + ROSI-
treated genotypes.
Tumours were differentially observed in tissues
among all groups, and were consistent with the pattern
of DMBA-initiated tumourigenesis (Table 1). In the
DMBA Only-treated group, PPARγ-WT mice had a
total tumour incidence of 80 ± 8% compared to 67 ± 8%
for PPARγ-MG KOs (Figure 1E). In the DMBA + ROSI
group, total tumour incidence was similar for PPARγ-
WTs (76 ± 7%) and PPARγ-MG KO (76 ± 10%) mice. In
DMBA Only-treated mice, mammary tumour inci-
dences were modestly higher among PPARγ-WTs (32 ±
9%) compared to PPARγ-MG KOs (26 ± 7%). In con-
trast, between DMBA + ROSI-treated strains, PPARγ-
MG KO mice had a ~2-fold higher mammary tumour
incidence compared to PPARγ-WTs (53 ± 12 vs. 29 ± 8%,
respectively), although this trend was not statistically sig-
nificant. Further, DMBA+ ROSI-treated PPARγ-MG KO
mice exhibited a ~2-fold higher incidence of mammary
tumours compared to DMBA Only-treated PPARγ-MG
KOs (53 ± 12% vs. 26 ± 7%, respectively) in a trend that
approached statistical significance (p = 0.07).
In DMBA Only-treated mice, PPARγ-MG KOs also
had a significant ~3.5-fold reduction in liver tumour
incidence compared to PPARγ-WTs (13 ± 5% vs. 48 ±
10%, respectively; p < 0.01). Cotreatment with DMBA +
ROSI halved liver tumour incidences in both
genotypes, although these changes were not signifi-
cantly different. Furthermore, PPARγ-MG KOs had a
significant ~4-fold decrease in thymic tumour
incidence compared to PPARγ-WT mice in the DMBA
Only-treated group (10 ± 5% vs. 40 ± 10%, respectively;
p < 0.05). Among cotreated groups, thymic tumour
incidences were not different between genotypes but
did significantly decrease by ~3-fold among PPARγ-
WT mice compared to their respective DMBA Only-
treated PPARγ-WT controls (p < 0.05).
Figure 1 In vivo effects of MG-specific PPARγ loss on survival and total tumour outcomes. Overall survival outcomes for (A) PPARγ-WT and
(B) PPARγ-MG KO mice are shown. Solid lines, DMBA Only treatment; broken lines, DMBA + ROSI treatment. Overall survival for (C) DMBA
Only- and (D) DMBA + ROSI-treated mice are shown. Solid lines, PPARγ-WTs; broken lines, PPARγ-MG KOs. (E) Tumour incidences are shown for
each strain across each treatment group for total, mammary, ovarian, liver, lung, skin and thymic tumours. *, p < 0.05; **, p < 0.01.
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stage (Figure 2A), DMBA Only-treated PPARγ-MG KO
mice exhibited a reduction in malignant mammary tu-
mours versus PPARγ-WTs (5 ± 4% vs. 20 ± 8%, respectively;
not significant). DMBA+ROSI cotreatment did not signifi-
cantly change PPARγ-WT malignant mammary tumour in-
cidence, but intriguingly, significantly increased malignant
mammary tumour incidence by ~8-fold in PPARγ-MG KO
mice (p < 0.01). For either genotype treated with DMBA
only versus DMBA+ROSI, the incidences of benign mam-
mary tumours were non-significantly reduced in PPARγ-
WTs (16 ± 7% vs. 12 ± 6% respectively) and PPARγ-MG
KOs (23 ± 7% vs. 18 ± 9%, respectively).
Mammary tumours were measured (length and width)
to monitor volumes as soon as they became palpable(Figure 2B) [16]. DMBA Only-treated PPARγ-MG KO
mice had a significant ~5-fold decrease in mean mam-
mary tumour volume compared to similarly treated
PPARγ-WTs (mean log volume: 360.6 mm3 vs. 1843 mm3,
respectively; p < 0.05). Cotreatment with DMBA+ ROSI
abolished this genotypic difference, and resulted in similar
mean mammary tumour volumes via increases in PPARγ-
WTs (806.9 mm3) and decreases in PPARγ-MG KOs
(818.0 mm3). The effects of treatment on mammary
tumour volumes within each genotype were not statisti-
cally significant.
Among PPARγ-WT mice, palpable mammary tumours
were first observed following DMBA treatment at week
11, and at week 13 in the DMBA + ROSI-treated group
(Figure 2C). With respect to mammary tumour latency,
Table 1 DMBA-induced tumours in PPARγ-WT and PPARγ-MG KO mice
DMBA Only-treated mice DMBA + ROSI-treated mice
PPARγ-WT (n = 25) PPARγ-MG KO (n = 39) PPARγ-WT (n = 34) PPARγ-MG KO (n = 17)
Mammary tumour type Tumours/Mouse (# Tumours)
Benign tumour 0.20 (5) 0.26 (10) 0.15 (5) 0.18 (3)
Squamous cyst 0.12 (3) 0.08 (3) 0.09 (3) 0.06 (1)
Spindle tumour 0.04 (1) − − −
Adenoma 0.04 (1) − 0.06 (2) −
Lipoma − 0.03 (1) − −
Other − 0.15 (6) − 0.12 (2)
Squamous cell carcinoma 0.08 (2) 0.03 (1) 0.26 (9) 0.29 (5)
Spindle cell carcinoma 0.08 (2) − − −
Adenocarcinoma − − 0.12 (4) −
Other carcinoma 0.08 (2) 0.03 (1) − 0.29 (5)
Total mammary tumours 0.44 (11) 0.31 (12) 0.53 (18) 0.76 (13)
Benign mammary 0.20 (5) 0.26 (10) 0.15 (5) 0.18 (3)
Malignant mammary 0.24 (6) 0.05 (2) 0.38 (13) 0.59 (10)
Non-mammary tumour/tissue affected Tumours/Mouse (# Tumours)
Skin 0.20 (5) 0.41 (16) 0.35 (12) 0.41 (7)
Ovarian/Uterine 0.24 (6) 0.26 (10) 0.26 (9) 0.13 (3)
Thymus 0.40 (10) 0.10 (4) 0.15 (5) 0.06 (1)
Spleen 0.04 (1) 0.03 (1) − −
Liver 0.48 (12) 0.13 (5) 0.26 (9) 0.06 (1)
Lung 0.20 (5) 0.08 (3) 0.15 (5) 0.06 (1)
Gastrointestinal 0.04 (1) 0.05 (2) 0.06 (2) 0.06 (1)
Lymphoma − 0.13 (4) 0.03 (1) −
Total tumours 2.04 (51) 1.46 (57) 1.79 (61) 1.59 (27)
Benign total 0.64 (16) 0.82 (32) 0.74 (25) 1.06 (18)
Malignant total 1.40 (35) 0.64 (25) 1.05 (36) 0.53 (9)
The number of breast tumours per mouse (multiplicity) is indicated with the total number in parenthesis. Mammary tumours were also sub-stratified and
expressed as multiplicity of benign, malignant, and metastatic tumours per genotype and treatment. Examples of benign mammary tumour subtypes are also
indicated. For non-mammary tissue, the numbers of each tumour per mouse is also indicated with the total number in parenthesis. Finally, total tumours were
sub-stratified and expressed as the multiplicity of benign, malignant, and metastatic tumours per genotype and treatment.
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palpable tumours by week 15, whereas this trended to-
ward week 21.5 in DMBA + ROSI-treated PPARγ-WT
mice. Interestingly, DMBA Only-treated PPARγ-MG
KOs first developed palpable tumours by week 13, in
comparison to DMBA + ROSI-treated PPARγ-MG KOs
in which palpable tumours were noted as early as week
10. Twenty-five percent of DMBA Only-treated PPARγ-
MG KO mice developed palpable mammary tumours by
week 25, and this significantly declined to week 16 in
DMBA + ROSI-treated PPARγ-MG KOs (p < 0.01). Simi-
larly, DMBA + ROSI-treated PPARγ-MG KOs showed a
significant decrease in mammary tumour latency com-
pared to similarly treated PPARγ-WT mice (with 25% of
mice developing palpable mammary tumours at week 16
vs. 21.5, respectively; p < 0.05).Representative sections of normal mammary tissue
and mammary tumours from PPARγ-WT and PPARγ-
MG KO mice in each treatment group were hematoxylin
and eosin (H&E) stained and examined in a blinded
fashion by collaborating pathologists for changes in mor-
phological characteristics. Untreated mammary glands
collected at week 12 from either strain were not mor-
phologically different from one another and exhibited
characteristic features of normally developed mammary
glands (Figure 3A and B). Both were comprised primarily
of adipocytes, as expected in the mouse mammary gland.
Tumours taken from PPARγ-WT mice treated with DMBA
Only were primarily classified as malignant carcinomas
with mixed squamous differentiation (Figure 3C). DMBA
Only-treated PPARγ-MG KO mammary tumours showed
comparatively more benign characteristics (Figure 3D). In
Figure 2 In vivo effects of MG-specific PPARγ deletion on mammary tumour incidence, tumour volume and latency. (A) Mammary tumour
incidences, as well as incidences of benign and malignant mammary tumours, are shown for each strain across each treatment group. **, p < 0.01.
(B) Mammary tumour volumes were calculated using the standard formula (L ×W2/2) and are expressed as mm3 on a log scale. Solid lines, mean
tumour volume for each strain; solid circles, PPARγ-WTs; open squares, PPARγ-MG KOs; *, p < 0.05. Mammary tumour latency is expressed as the
percentage of palpable mammary tumours within (C) PPARγ-WT and (D) PPARγ-MG KO strains in a given week. Solid lines, DMBA Only treatment;
broken lines, DMBA + ROSI treatment.
Apostoli et al. Molecular Cancer  (2015) 14:85 Page 5 of 14DMBA + ROSI-treated mice, mammary tumours iso-
lated from PPARγ-WT mice were primarily identified as
squamous cell carcinomas (Figure 3E); whereas, those
from PPARγ-MG KO mice were classified as more ma-
lignant lesions that ranged from well-to-moderately dif-
ferentiated (Figure 3F).
To evaluate protein expression changes in situ, mean
fluorescence intensities of target proteins were quanti-
fied in three regions within each analyzed mammary
tumour (Figure 4A). BRCA1 was evaluated in this man-
ner because it is a known tumour suppressor gene,
whose gene promoter contains a PPRE [17]. Mammaryglands from untreated strains, included for reference
(Additional file 1: Figure S1), illustrate decreased PPARγ
and BRCA1 expression in cytokeratin-positive MG cells
in PPARγ-MG KO mice compared to PPARγ-WTs.
Results show no differences in both PPARγ and BRCA1
among mammary-derived tumours from DMBA-treated
PPARγ-MG KO and PPARγ-WT mice (PPARγ: 1822 ±
999 vs. 1459 ± 377, respectively and BRCA1: 1007 ± 432
vs. 1280 ± 258, respectively) (Figure 4B). Compared to
DMBA Only-treated controls, irrespective of genotype,
mammary tumours from mice treated with DMBA+ ROSI
trended toward increased PPARγ expression accompanied
Figure 3 Pathological effect of MG cell-specific PPARγ deficiency on
DMBA-induced mammary tumours. Mice were treated as described
in the Methods section. Representative sections are shown. (A),
untreated PPARγ-WT mammary gland; (B), untreated PPARγ-MG KO
mammary gland; (C), DMBA Only-treated PPARγ-WT mammary
tumour; (D), DMBA Only-treated PPARγ-MG KO mammary tumour;
(E), DMBA + ROSI-treated PPARγ-WT mammary tumour; (F), DMBA +
ROSI-treated PPARγ-MG KO mammary tumour. All photos taken at ×
200. Scale bar, 50 μm.
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DMBA + ROSI treatment significantly increased BRCA1
expression ~3.5-fold in PPARγ-WT mice compared to
both DMBA Only-treated PPARγ-WTs (4400 ± 915 vs.
1280 ± 258, respectively; p < 0.01), and DMBA + ROSI-
treated PPARγ-MG KOs (1707 ± 180; p < 0.01).
Protein expression changes were determined by
immunoblotting in mammary tumours from DMBA
Only- and DMBA+ ROSI-treated strains (Figure 5A). Un-
treated mammary tissues from PPARγ-WT and PPARγ-
MG KO mice illustrate PPARγ is reduced in the latter
and are representative of results from multiple inde-
pendent experiments. Densitometric analyses of protein
expression within mammary tumours revealed surpris-
ingly similar PPARγ protein levels irrespective of geno-
type or treatment (Figure 5B). Intriguingly, DMBA +
ROSI-treated PPARγ-MG KO mammary tumours ex-
hibited a significant ~4-fold increase in Cox-2 com-
pared to DMBA Only-treated PPARγ-MG KOs (p <
0.01), as well as a significant ~3-fold increase in Cox-2
compared to DMBA + ROSI-treated PPARγ-WT mice
(p < 0.01). A significant ~6-fold reduction in PTEN was
observed among DMBA Only-treated PPARγ-MG KOs
compared to similarly treated control mice (p < 0.0001).
No change in PTEN expression was observed among
DMBA Only- and DMBA + ROSI-treated PPARγ-MG
KOs; however, it was interesting to note that ROSI
cotreatment produced a significant ~4-fold reduction inPTEN in PPARγ-WT mice compared to DMBA Only-
treated controls (p < 0.0001).
A 23-plex cytokine array was performed on serum
samples from both PPARγ-WT and PPARγ-MG KO
strains for untreated, DMBA Only-treated, and DMBA
+ ROSI-treated mice (Figure 6). Among untreated mice,
there were significantly lower levels of GM-CSF (~2.5-
fold; p < 0.05) observed in PPARγ-MG KOs compared
to PPARγ-WT mice (Table 2). DMBA + ROSI treatment
significantly reduced serum GM-CSF (~3.5-fold; p <
0.01), and non-significantly decreased serum eotaxin
(~11-fold; p < 0.10), in PPARγ-MG KO mice compared
to similarly treated PPARγ-WTs. Interestingly, PPARγ-
MG KOs showed significantly lower levels of serum
IL-4 (p < 0.01), IL-10 (p < 0.001), IL-13 (p < 0.05), eotaxin
(p < 0.01), GM-CSF (p < 0.0001), IFN-γ (p < 0.05) and
MIP-1α (p < 0.01), as well as a trend toward reduced levels
of KC (p = 0.08), compared to PPARγ-WTs.
Given their putative relevance to mammary tumour
growth, serum VEGF, leptin and PGE metabolites were
also quantified by separate ELISA experiments in both
untreated strains and those treated with DMBA alone
or DMBA + ROSI (Table 2). No significant differences
were observed in serum leptin and PGE metabolite
levels between genotypes or treatment groups. In con-
trast, DMBA Only-treated PPARγ-MG KOs had signifi-
cantly ~3-fold lower serum VEGF levels compared to
similarly treated PPARγ-WTs (p < 0.05). VEGF expres-
sion was also significantly reduced ~4-fold in DMBA +
ROSI compared to DMBA Only levels in PPARγ-WTs
(p < 0.05), but not PPARγ-MG KOs.
Discussion
Given recent evidence implicating a protective role for
PPARγ in breast cancer [12,13,14], the MG cell-
specific contribution of this receptor was evaluated
during DMBA-induced breast tumourigenesis using
PPARγ-MG KO and PPARγ-WT mice. Cotreatment
with a gold standard PPARγ activator, ROSI, further
provided the ability to identify PPARγ-dependent anti-
breast tumour progression signaling pathways specific
to MG cells. Other groups have examined the MG-
specific contribution of PPARγ in breast cancer, using
overexpression [18] and dominant negative knockout
[19] approaches that only target the PPARγ1 isoform.
Here, the Cre-loxP system was used to delete expres-
sion of both PPARγ protein isoforms, and thus, elimin-
ate any confounding compensatory effects. In addition,
the ROSI dose and regimen used here was previously
shown to effectively activate PPARγ signaling [20-22]
and achieve serum glucose profiles within human thera-
peutic ranges in mice [23,24]. Surprisingly, it was dis-
covered that PPARγ-MG KO mice are protected more
so than PPARγ-WTs during DMBA-mediated breast
Figure 4 PPARγ and BRCA1 expression in DMBA-mediated mammary-derived tumours. (A) Representative immunofluorescence images illustrating
expression of cell nuclei (DAPI; in blue), PPARγ or BRCA1 (in green) and cytokeratin (CK; in red), with an accompanying composite image, in
mammary-derived tumours from PPARγ-WT and PPARγ-MG KO mice. All photos taken at × 600. Scale bar, 50 μm. (B) Quantification of global
mean fluorescence intensity for PPARγ or BRCA1 in tumours was performed using Image Pro Plus software. **, p < 0.01.
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rescues PPARγ-WTs but renders PPARγ-MG KOs more
susceptible to breast tumour progression. These find-
ings suggest that PPARγ expression within MG cells
may be a strong candidate biomarker for identifying
patient populations with aggressive breast tumours, as
well as aid in predicting patients likely to benefit from
novel chemotherapeutic use of PPARγ activating drugs.
The findings that PPARγ-MG KO mice respond more
favourably, for example in OS, than PPARγ-WTs follow-
ing tumourigenic initiation by DMBA, but do worse fol-
lowing cotreatment with a PPARγ activating ligand were
unexpected. These surprising outcomes may be explained,
at least in part, by the increased total mammary tumour
and malignant mammary tumour incidences, and de-
creased mammary tumour latency, that were observed inDMBA+ ROSI-treated PPARγ-MG KOs compared to
those treated with DMBA alone. Collectively, these find-
ings suggest that PPARγ expression in MG cells and ROSI
activation in mice lacking MG-specific PPARγ is poten-
tially harmful during chemical-mediated breast tumour
progression. Given that ROSI activation produced detri-
mental effects exclusive to knockout mice suggests that
PPARγ-independent effects of this drug may be partly re-
sponsible [25]. These interesting observations underscore
the importance of personalized medicine, and the need for
characterizing normal breast and mammary tumour epi-
thelial expression of PPARγ before considering TZD-
like drugs as chemotherapeutic strategies for breast
cancer patients. ROSI may still represent a viable che-
motherapeutic option if expression of MG cell-specific
PPARγ remains intact.
Figure 5 Molecular analysis from untreated mammary glands and DMBA-induced mammary tumours. (A) Representative protein expression
changes within untreated mammary glands (MG) and in vivo generated mammary tumours in DMBA Only- and DMBA + ROSI-treated groups
were analyzed by Western Blot as described in the Methods section. PPARγ, Cox-2 and PTEN protein levels were analyzed in untreated virgin MG
from PPARγ-WT (WT) and PPARγ-MG KO (MG KO) mice, as well as all available breast tumour subtypes from both strains of mice. β-actin served as
loading control. (B) Densitometry for PPARγ, Cox-2 and PTEN were performed on all mammary tumours using ImageJ software, and expressed as
mean ± SD. Fold changes are relative to mammary tissue from untreated PPARγ-WT. Black bars, PPARγ expression; white bars, Cox-2 expression;
grey bars, PTEN expression; **, p < 0.01; ****, p < 0.0001.
Figure 6 Heatmap reconstruction of 23-plex cytokine analyses resulting from MG-specific PPARγ loss. A heatmap generated from a 23-plex
cytokine array illustrating serum concentrations of cytokines from untreated, DMBA Only- and DMBA + ROSI-treated PPARγ-WT and PPARγ-MG KO
strains. Mean cytokine concentrations (pg/ml) are visually represented on a log scale with red, black and green indicating high, median and low,
respectively (refer to colour bar). IL-9 and IL-12(p70) were omitted from the table since values were below the level of detection.
Apostoli et al. Molecular Cancer  (2015) 14:85 Page 8 of 14














Cytokine [signif] mean ± SD; all values expressed as pg/ml
IL-1α 90.6 ± 56.6 93.9 ± 106.3 48.9 ± 32.9 177.0 ± 206.4 39.8 ± 66.1 36.8 ± 46.0
IL-1β 372.6 ± 105.3 3016.0 ± 5279.0 309.0 ± 74.0 195.4 ± 25.9 870.9 ± 1383.0 116.7 ± 91.1
IL-2 62.8 ± 47.0 42.4 ± 27.9 64.6 ± 80.3 34.9 ± 15.0 24.8 ± 6.1 41.8 ± 32.9
IL-3 6.8 ± 15.2 63.4 ± 111.5 16.0 ± 13.6 12.9 ± 6.6 25.4 ± 40.9 6.8 ± 5.6
IL-4 [gg] 16.1 ± 7.9 16.4 ± 3.2 20.1 ± 10.0 11.8 ± 1.5 10.4 ± 1.2 11.0 ± 1.1
IL-5 40.0 ± 16.3 280.7 ± 454.0 23.2 ± 17.2 ND 77.4 ± 154.8 4.6 ± 9.3
IL-6 18.0 ± 16.4 215.5 ± 387.5 20.7 ± 12.0 5.7 ± 1.5 62.7 ± 106.6 14.5 ± 8.5
IL-9 ND ND ND ND ND ND
IL-10 [ggg] 97.3 ± 64.6 163.2 ± 114.2 117.6 ± 48.8 23.5 ± 9.5 39.7 ± 19.9 52.0 ± 20.9
IL-12(p40) [tt] 694.9 ± 299.5 1212.0 ± 302.4 625.3 ± 314.0 554.5 ± 176.1 971.7 ± 306.8 665.1 ± 227.3
IL-12(p70) ND ND ND ND ND ND
IL-13 [g] 654.1 ± 638.6 410.6 ± 437.3 440.6 ± 380.4 95.4 ± 71.7 124.9 ± 33.2 248.0 ± 91.7
IL-17A 32.3 ± 23.8 588.5 ± 1114.0 34.9 ± 19.5 2.1 ± 3.2 150.3 ± 294.5 7.8 ± 12.6
Eotaxin [gg] 1552.0 ± 1593.0 1141.0 ± 890.4 2016.0 ± 743.7 400.4 ± 397.5 620.8 ± 482.6 188.4 ± 163.4
G-CSF 199.6 ± 85.9 1631.0 ± 929.1 3393.0 ± 5274.0 149.1 ± 46.6 564.3 ± 375.5 433.7 ± 121.9
GM-CSF [gggg] 420.2 ± 218.5 384.4 ± 86.8 375.3 ± 94.4 173.0 ± 68.1 * 148.6 ± 47.4 110.1 ± 75.6 Δ
IFN-γ [g] 35.4 ± 38.6 26.6 ± 10.5 23.9 ± 11.3 15.3 ± 6.8 6.8 ± 6.4 9.6 ± 7.0
KC 46.4 ± 62.2 25.3 ± 9.4 41.1 ± 28.2 8.8 ± 1.6 23.1 ± 11.5 14.9 ± 2.4
MCP-1 218.2 ± 132.6 1062.0 ± 1493.0 286.4 ± 156.2 75.8 ± 38.7 190.7 ± 132.6 95.9 ± 17.7
MIP-1α [gg] 67.2 ± 47.2 87.8 ± 38.9 82.5 ± 54.7 45.1 ± 15.2 26.3 ± 8.9 37.1 ± 11.4
MIP-1β 51.9 ± 36.9 525.1 ± 909.0 39.4 ± 13.2 15.2 ± 4.0 185.8 ± 335.4 17.4 ± 15.8
RANTES 31.5 ± 23.1 71.6 ± 76.2 40.7 ± 19.4 37.1 ± 8.5 82.1 ± 97.6 27.2 ± 3.9
TNF-α 1128.0 ± 992.2 19244.0 ± 36869.0 538.0 ± 207.5 272.8 ± 81.9 5763.0 ± 10948.0 363.3 ± 352.8
VEGF 144.6 ± 32.8 (7) 489.7 ± 420.8 (3) ** 132.8 ± 33.7 (4) # 254.4 ± 57.0 (8) 167.5 ± 40.9 (4) # 137.3 ± 22.4 (4)
Leptin 22290.0 ± 11260.0 (7) 8040.0 ± 1968.0 (3) 25820.0 ± 18020.0 (4) 13680.0 ± 1899.9 (8) 32140.0 ± 40310.0 (4) 39560.0 ± 44040.0 (4)
PGE Metabolites 560.1 ± 676.7 (5) 76.7 ± 13.7 (4) 93.9 ± 51.6 (4) 141.3 ± 122.2 (4) 335.0 ± 158.5 (3) 229.0 ± 202.7 (3)
Concentrations reported as mean ± standard deviation (SD) and expressed as pg/ml. Except for VEGF, leptin, and PGE metabolites, which were analyzed with
separate ELISA kits, all cytokine concentrations were obtained by a multiplex array. *, significantly different from Untreated PPARγ-WT, p < 0.05; **, significantly
different from Untreated PPARγ-WT, p < 0.01; #, significantly different from DMBA Only-treated PPARγ-WT, p < 0.05; Δ, significantly different from DMBA +
ROSI-treated PPARγ-WT, p < 0.05. g, genotype different, p < 0.05; gg, genotype different, p < 0.01; ggg, genotype different, p < 0.001; gggg, genotype different,
p < 0.0001; tt, treatment different p < 0.01; ND, not detectable.
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observed in these studies, both MG-specific PPARγ defi-
ciency and activation produced similar results. Although
paradoxical, these comparable outcomes may reflect simi-
lar signaling pathways resulting from cofactor mobility.
For example, in the PPARγ-MG KO model, coactivators
and/or corepressors normally bound by the PPARγ/RXRα
complex may be released to interact with their down-
stream signaling targets and exert their intended effects
similar to when PPARγ is activated. This may partially
explain why DMBA Only-treated PPARγ-MG KOs havebetter OS compared to DMBA Only-treated PPARγ-WTs,
but comparable to PPARγ-WTs treated with DMBA+
ROSI. A similar mechanism has been reported in a PPARβ
KO mouse model, whereby an antiinflammatory corepres-
sor (Bcl-6) is free to exert its effects in both PPARβ-
deficient and PPARβ-activated cell contexts [26].
RNAseq and ChIPseq assays evaluating global PPARγ/
RXRα interactions with specific cofactors and gene tar-
gets would help clarify if this mechanism is involved in
the context of breast tumourigenesis, but is beyond the
scope of these studies.
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confirmed in untreated PPARγ-WT but abolished in
PPARγ-MG KO mammary glands. Importantly, ROSI
cotreatment increased PPARγ expression in mammary-
derived lymphomas and carcinomas from PPARγ-WT
and PPARγ-MG KO mice, but only specifically aug-
mented BRCA1 in PPARγ-WTs. BRCA1 is a critical
tumour suppressor gene that possesses a PPRE within its
promoter region [17]. We have previously demonstrated
that BRCA1 expression can be upregulated in fat cells via
adipocyte-specific PPARγ activation [13]. Accordingly, the
current study provides similar evidence that BRCA1 is a
target of PPARγ in MG cells. This specific interaction
may contribute to the improved outcomes observed
among DMBA+ROSI-treated PPARγ-WT mice, via
BRCA1-mediated DNA damage repair and/or blocking
aromatase-dependent estrogen production [27].
Cox-2 is a key PG-synthesizing enzyme and a breast
cancer prognostic marker of poor outcome [28]. Conse-
quently, Cox-2 protein expression is observed in many
epithelial tumours, including breast cancer [29], with in-
creasing levels associated with advanced tumour grade
[30,31]. ROSI cotreatment repressed Cox-2 in PPARγ-
WT tumours, but dramatically amplified it in PPARγ-
MG KOs. This marked increase in Cox-2 protein levels
among DMBA + ROSI-treated PPARγ-MG KO tumours
may partially explain the poor survival and mammary
tumour outcomes within this study group. Indeed, Cox-
2 promotes aromatase transcription [32] and renders
cells resistant to apoptosis and even chemotherapy [31];
however, some of these properties may be mediated by
PG levels. That we did not observe any significant differ-
ences with respect to serum PGE levels in any group
provides evidence that other PG products, or perhaps
even Cox-2 activity independent of PG production, may
be involved in this setting and requires further study.
Although the Cox-2 gene contains a PPRE within its
promoter [33,34], PPARγ-dependent and PPARγ-
independent mechanisms both positively and negatively
regulate Cox-2 gene transcription depending on cell-
and stimulus-specific contexts [33,35,36,37]. Given Cox-
2 expression was lower in DMBA + ROSI-treated
PPARγ-WT tumours suggests MG cell-specific PPARγ
activation may play a role in suppressing Cox-2 protein
levels, which is similar to our findings with respect to
mammary secretory epithelial-PPARγ [14]. On the other
hand, DMBA + ROSI-treated PPARγ-MG KO tumours
showed a dramatic increase in Cox-2 protein levels sug-
gesting that a PPARγ-independent process is likely re-
sponsible. It has been demonstrated that PPARγ ligands
activate Cox-2 transcription via receptor-independent
stimulation of the MAPK-NF-κB pathway [38,39].
Moreover, PPARγ-independent activation of the gluco-
corticoid receptor by ROSI may also be responsible forincreased Cox-2 gene expression [40,41], although this
remain to be proven.
The PTEN gene promoter also reportedly contains a
PPRE [33,34], and so it was not surprising that PTEN
protein levels were markedly reduced among PPARγ-
MG KO mammary tumours in the DMBA Only group.
Interestingly, DMBA+ ROSI-treated PPARγ-WT mice
had reduced PTEN expression among mammary tumours
than observed in mammary tumours from respective
DMBA Only controls. This may be reflective of the de-
creased mammary tumour progression in DMBA+ROSI-
treated PPARγ-WT mice. Taken together, these data sug-
gest PPARγ is required for normal PTEN expression in
malignant mammary tumours, but PTEN is not an early
PPARγ downstream signaling target in benign mammary
tumours, and may be a fruitful area for research in future
studies.
Variable PPARγ protein levels were observed among
mammary tumours from PPARγ-WT and PPARγ-MG
KO by Western blot analysis. Among PPARγ-WT tu-
mours, the variable pattern may reflect alternative path-
ways acquired during tumourigenic progression of
initiated cells, some of which may silence PPARγ expres-
sion. There are indeed reports that PPARγ levels decline
as human breast tissue becomes increasingly malignant
[42], which is consistent with our hypothesis of its role
as a suppressor of breast tumour progression. Alterna-
tively, the inherent cellular heterogeneity of these mam-
mary tumours, that likely contain differing amounts of
PPARγ expressing stromal adipocytes, endothelial cells
and immune cells, may contribute to the observed vari-
ability. Although a possible mosaic expression pattern of
the MMTV promoter [43] cannot be discounted, differ-
ing percentages of stromal PPARγ expressing cells may
also explain the variability of PPARγ expression ob-
served in PPARγ-MG KO mammary tumours. This is
supported by our IF data showing specificity and extent
of PPARγ deletion among mammary epithelial cells of
untreated PPARγ-MG KO mice. It is also possible that
other non-mammary epithelial cell sources of PPARγ
signaling may have contributed to the outcomes of these
in vivo tumourigenesis studies. We previously showed
that mammary adipocyte-specific PPARγ blocks breast
tumour progression in part via upregulation of BRCA1
[13]. Interestingly, in the present study, treatment with
ROSI caused induction of BRCA1 expression in PPARγ-
WT, but not PPARγ-MG KO mouse mammary tumours.
This suggests activation of PPARγ may protect against
breast tumour progression only when mammary
epithelial-stromal crosstalk contains functional PPARγ
signaling in both cell types, and is the focus of additional
studies beyond the scope of this work.
Untreated knockout serum contained lower levels of
known proinflammatory and chemotactic cytokines,
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other contextually-dependent proinflammatory signals,
such as IL-4 and GM-CSF [45], that could have possibly
rendered PPARγ-MG KOs less susceptible to breast can-
cer compared to PPARγ-WTs when challenged with
DMBA. DMBA + ROSI cotreatment also rescued
PPARγ-WTs via downregulation of serum VEGF. This
may be the result of direct PPARγ activity via a PPRE in
the VEGF promoter [47], or indirectly via other PPARγ
targets such as BRCA1, which can silence VEGF expres-
sion and secretion [48], or Cox-2, which can induce
VEGF expression [49].
Irrespective of treatment, all PPARγ-MG KOs exhib-
ited significantly lower levels of serum IL-4, IL-10, IL-
13, eotaxin, GM-CSF, IFN-γ and MIP-1α compared to
PPARγ-WT mice. This is particularly intriguing because
these cytokines are commonly produced by macro-
phages and T lymphocytes [44,46,50,51]. Given that this
cytokine expression pattern is genotype-specific raises
the possibility that PPARγ-MG KO mice possess fewer
macrophages and T cells, and thus experience reduced
inflammation, compared to PPARγ-WTs. This explan-
ation may provide another layer why knockout mice
were less susceptible to breast tumourigenesis when
challenged with DMBA.
Conclusion
A summary of MG-specific PPARγ loss (Figure 7) illus-
trates that reduced serum expression of the proinflam-
matory cytokines, IL-4, eotaxin, GM-CSF, IFN-γ, andFigure 7 Big picture summary of the effects of MG-specific PPARγ loss. PPA
and chemotactic cytokines (IL-4, eotaxin, GM-CSF, IFN-γ, and MIP-1α) which
Only-mediated carcinogenesis compared to PPARγ-WTs. Activation of PPAR
increasing BRCA1 and suppressing VEGF and Cox-2 expression, effectively resc
PPARγ expression, DMBA-induced breast tumour progression is enhanced
activation of Cox-2.MIP-1α, rendered PPARγ-MG KO mice less susceptible
than PPARγ-WTs to DMBA-mediated breast tumouri-
genesis. Here we provide the first in vivo evidence that
PPARγ activation in MG cells blocks breast tumour
progression in PPARγ-WTs by upregulating BRCA1,
and downregulating VEGF and Cox-2, expression. Fi-
nally, PPARγ-independent activation of Cox-2 enhanced
breast tumourigenesis in PPARγ-MG KO mice. This
study provides insight into the MG cell-specific role of
PPARγ during DMBA-mediated breast tumour progres-
sion. The results suggest PPARγ signaling in MG cells
may be required during early mammary tumourigenesis;
however, activation of PPARγ within this cell population
is protective against the growth and spread of breast tu-
mours. In sharp contrast, when PPARγ signaling is dis-
rupted in MG cells, the use of activating PPARγ ligands
exert a deleterious PPARγ-independent effect. Together,
these data emphasize the use of PPARγ ligands may be
beneficial as novel chemotherapeutic agents for the
treatment of a subpopulation of breast cancer patients,
and that PPARγ expression may serve as a strong
predictive biomarker of patient response.
Materials and methods
Animals
All mice were housed and treated in accordance with
Canadian Council for Animal Care (CCAC) guidelines
under animal protocols approved by the Queen’s
University Animal Care Committee (UACC) as previously
described [14]. Transgenic mice expressing the MMTV-Rγ-MG KO mice have decreased serum levels of proinflammatory
may, in part, contribute to their decreased susceptibility to DMBA
γ in MG cells suppresses breast tumourigenesis in PPARγ-WT mice by
uing PPARγ-WT mice from breast tumour progression. In MG cells lacking
by cotreatment with a PPARγ activator, due to PPARγ-independent
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pository (Frederick, Maryland), and crossed with our pre-
viously generated PPARγ(fl/fl);Cre− (PPARγ-WT) mice [20],
to produce PPARγ(fl/fl);MMTV-LTR-Cre+ (PPARγ-MG
KO) mice. Mouse genotypes were confirmed by PCR ana-
lysis (Additional file 2: Figure S2) as before [12].
In vivo breast tumourigenesis
At age 8-12 weeks, PPARγ-WT and PPARγ-MG KO vir-
gin female mice received 1 mg DMBA (Sigma-Aldrich,
D3254) by gavage once/week for 6 weeks. At week 7,
randomized mice either continued on a regular chow
diet (DMBA Only: PPARγ-WT, n = 25 and PPARγ-MG
KO, n = 39) or received a PPARγ ligand (ROSI; 4 mg/kg/
day)-supplemented chow diet (DMBA + ROSI: PPARγ-
WT, n = 34 and PPARγ-MG KO, n = 17) for the study
duration. Mice were monitored for tumourigenic changes
for 25 weeks, and tumour samples were harvested as
previously described [13]. Non-fasted submandibular
blood was obtained pre-, mid- and end-study, and sepa-
rated to obtain serum samples that were frozen in liquid
N2 for future analysis. Pathological staging of tumours
was performed in a blinded fashion by collaborating
pathologists.
Immunofluorescent (IF) staining
Formalin-fixed paraffin-embedded untreated mammary
glands and mammary tumours from PPARγ-WT and
PPARγ-MG KOs in each treatment group were sec-
tioned and stained as described previously [14]. Sections
were stained with primary antibodies for pan-cytokeratin
(Dako, M3515; 1:500 dilution) and PPARγ (Santa Cruz,
sc-7196; 1:500 dilution) or BRCA1 (Santa Cruz, sc-7867;
1:500 dilution). Secondary antibodies used were donkey
α-rabbit FITC (Santa Cruz, sc-2090; 1:500 dilution) and
α-mouse Alexa Fluor 594 (Invitrogen, A11005; 1:500 di-
lution). Slides were coverslipped with mounting media
containing DAPI stain (Vectashield). IF staining was vi-
sualized with a BX51 System Microscope (Olympus).
Images were acquired with QCapture Pro 5.1 software
(QImaging) and analyzed with Image-Pro Plus 6.0 soft-
ware (Media Cybernetics).
Immunoblotting
Whole-cell extracts were prepared from normal and
tumour tissue samples from PPARγ-WT and PPARγ-
MG KO mice as previously described [14]. Protein con-
centrations were quantified using the DC protein assay
(BioRad). Proteins were detected with primary anti-
bodies for PPARγ (Santa Cruz, sc-7273; 1:500 dilution),
β-actin (Santa Cruz, sc-47778; 1:000 dilution), Cox-2
(Cayman Chemical, #160126; 1:500 dilution) and PTEN
(Cell Signaling, #9559; 1:1,000 dilution) followed by appro-
priate HRP-conjugated secondary goat α-mouse (SantaCruz, sc-2005; 1:10,000 dilution) or goat α-rabbit (Santa
Cruz, sc-2004; 1:10,000 dilution) antibodies. Protein ex-
pression was assessed using ImageJ analysis software
(rsbweb.NIH.gov).
Serum assays
A Bio-Plex Pro Mouse Cytokine 23-plex serum assay kit
(BioRad Laboratories) was used to assess cytokine con-
centrations of IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17A,
eotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1α,
MIP-1β, RANTES, and TNF-α as previously described
[14]. Clustering and heat map analyses were performed
with Cluster 3.0 and TreeView software (Stanford Uni-
versity). Serum VEGF, leptin and prostaglandin E (PGE)
metabolites were analyzed using ELISA kits as per man-
ufacturer’s (Cayman Chemical) instructions. All cytokine
concentrations are reported as the mean ± standard devi-
ation (SD) pg/ml.
Statistical analysis
Differences between genotype and treatment groups
were assessed using a Two-Way analysis of variance
(ANOVA), followed by a Tukey’s post-hoc test for group
comparisons. Survival was analyzed using a Log Rank
test, and proportions were assessed using Chi-square
analysis. GraphPad Prism (Version 6.0) software was
used for all analyses. A value of p < 0.05 was considered
statistically significant.
Additional files
Additional file 1: Figure S1. PPARγ and BRCA1 expression in untreated
tissue. Representative immunofluorescence images illustrating expression
of cell nuclei (DAPI; in blue), PPARγ or BRCA1 (in green) and cytokeratin
(CK; in red), with an accompanying composite image, in untreated virgin
mammary tissue from PPARγ-WT and PPARγ-MG KO mice. All photos
taken at × 600. Scale bar, 50 μm.
Additional file 2: Figure S2. Mouse genotyping of PPARγ. Mice were
genotyped using a standard polymerase chain reaction (PCR) assay as
previously described [12]. Representative PCR results obtained using DNA
isolated from tails of (n = 3) PPARγ-WT and PPARγ-MG KO mice. Floxed
PPARγ allele, ~285 bp; Cre-mediated recombined null allele, ~450 bp.
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